Intracranial Hemorrhage following Lumbar Puncture in a Patient on Apixaban

Priyanka Vijapura1, Michael J Maniaci1

  • 1Division of Hospital Internal Medicine, Mayo Clinic, Jacksonville, Florida, USA.

Case Reports in Neurology
|October 15, 2019
PubMed

Insights

Emergent lumbar puncture in patients on direct oral anticoagulants (DOACs) lacks evidence-based guidelines. A case report highlights subdural hematomas after lumbar puncture in a patient taking apixaban, underscoring bleeding risks.

Area of Science:

  • Neurology
  • Hematology
  • Pharmacology

Background:

  • Clinical practice guidelines for emergent lumbar puncture in patients on direct oral anticoagulants (DOACs) are absent, relying on expert opinion.
  • Direct oral anticoagulants (DOACs) are increasingly prescribed for conditions like nonvalvular atrial fibrillation.

Observation:

  • An 80-year-old female on therapeutic apixaban for atrial fibrillation underwent lumbar puncture for suspected meningitis.
  • The patient subsequently developed bilateral subdural hematomas.

Findings:

  • This case highlights the potential risk of intracranial hemorrhage, specifically subdural hematomas, following lumbar puncture in patients anticoagulated with DOACs.
  • Current criteria for pre-lumbar puncture brain imaging are reviewed in the context of DOAC use.

Implications:

  • There is a critical need for evidence-based guidelines on managing emergent lumbar punctures in patients taking DOACs.
  • Further research is warranted to establish clear protocols and mitigate bleeding risks associated with lumbar puncture in this patient population.